ORIGINAL ARTICLE

Polymorphism rs3123554 in the cannabinoid receptor gene type 2 (CNR2) reveals effects on body weight and insulin resistance in obese subjects

Daniel Antonio de Luis*, Olatz Izaola, David Primo, Beatriz de la Fuente, Rocio Aller

Center of Investigation of Endocrinology and Nutrition, Medicine School and Dpt of Endocrinology and Investigation, Hospital Clinico Universitario, University of Valladolid, Valladolid, Spain

Received 23 March 2017; accepted 16 June 2017
Available online 7 August 2017

Abstract
Background: Few studies assessing the relationship between single nucleotide polymorphisms in CNR2 and obesity or its related metabolic parameters are available.
Objective: To investigate the influence of polymorphism rs3123554 in the CNR2 receptor gene on obesity anthropometric parameters, insulin resistance, and adipokines in subjects with obesity.
Design: The study population consisted of 1027 obese subjects, who were performed bioelectrical impedance analyses, blood pressure measurements, serial assessments of dietary intake during three days, and biochemical tests.
Results: Genotypes GG, GA, and AA were found in 339 (33.0%), 467 (45.5%), and 221 (21.5%) respectively. Body mass index, weight, fat mass, waist circumference, insulin, HOMA-IR, and triglyceride and leptin levels were higher in A-allele carriers as compared to non A-allele carriers. No differences were seen in these parameters between the GA and AA genotypes. There were no statistical differences in dietary intake.
Conclusion: The main study finding was the association of the minor allele of the SNP rs3123554 in the CNR2 gene with body weight and triglyceride, HOMA-IR, insulin, and leptin levels.

© 2017 SEEN y SED. Published by Elsevier España, S.L.U. All rights reserved.

Keywords
Adipokines; Cannabinoid receptor gene type 2; Obesity; Polymorphism; Insulin resistance

Resumen
El polimorfismo rs3123554 en el gen receptor canabinoide tipo 2 (CNR2) se relaciona con el peso corporal y la resistencia a la insulina en obesos

Antecedentes: Existen pocos estudios que evalúen la relación entre los polimorfismos de un único nucleótido CNR2 y la obesidad o sus parámetros metabólicos.

* Corresponding author.
E-mail address: dadluis@yahoo.es (D.A. de Luís).

http://dx.doi.org/10.1016/j.endinu.2017.06.001
2530-0164/© 2017 SEEN y SED. Published by Elsevier España, S.L.U. All rights reserved.
Obesidad; Polimorfismo; Resistencia a la insulina

Objetivo: El objetivo de nuestro estudio fue investigar la influencia del polimorfismo rs3123554 del gen del receptor CNR2 sobre los parámetros antropométricos de la obesidad, la resistencia a la insulina y las adipocitoicas en sujetos con obesidad.

Diseño: Se analizó una población de 1.027 sujetos obesos. Se determinó la masa grasa con bioimpedancia eléctrica, se midió la presión arterial, se evaluó la ingesta nutricional durante 3 días y se realizó un análisis bioquímico.

Resultados: Del total, 339 pacientes (33,0%) tuvieron el genotipo GG, 467 pacientes GA (45,5%) y 221 pacientes AA (21,5%). El índice de masa corporal, peso, masa grasa, circunferencia de cintura, insulina, HOMA-IR, triglicéridos y niveles de leptina fueron mayores en los portadores de alelo A que en los no portadores. No se detectaron diferencias en estos parámetros entre los genotipos GA y AA. No se detectaron diferencias estadísticas en la ingesta dietética.

Conclusión: El principal hallazgo de este estudio es la asociación del alelo menor (A) de rs3123554 SNP del gen CNR2 con el peso corporal y los triglicéridos, HOMA-IR, la insulina y los niveles de leptina.

© 2017 SEEN y SED. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

In Western countries, the prevalence of obesity with related diseases diabetes mellitus, hypertension and dyslipemia is still growing and has reached epidemic proportions. Not only environmental, but also genetic factors contribute to the development of obesity.1

In this scenario, the important role played by the endocannabinoid system is emerging. The cannabinoid receptor system consists of two receptors (CNR1 and CNR2). CNR1 is mainly located in the brain: its role in eating behavior is well established and has already led to therapeutically approaches in the treatment of obesity.2 In contrast, CNR2 has been referred to as the peripheral cannabinoid receptor isoform that is mainly expressed in cells of the immune system. The endogenous cannabinoid system mediates and is positioned both functionally and anatomically3 to be an important modulator of normal human brain behavior. This system consists of endogenous ligands 2-arachidonoylglycerol (2-AG) and anandamide (ADA), and the above-mentioned two types of G-protein-coupled cannabinoid receptor. A greater insight into the endocannabinoid system has been derived from studies in animals with a genetic deletion of the CNR1 receptor, which have a lean phenotype and are resistant to diet-induced obesity and the associated insulin resistance induced by a high palatable high-fat diet.4 Otherwise, a single nucleotide polymorphism rs1049353 of the CNR1 gene resulting in the substitution of the G to A at nucleotide position 1359 in codon 435 (Thr), was reported as a common polymorphism in Caucasian population,5-7 with metabolic implications. Interestingly, there is few evidence of CNR2 SNPs and obesity or its related metabolic parameters.

The aim of our study was to investigate the influence of the polymorphism (rs3123554) of CNR2 receptor gene on obesity anthropometric parameters, insulin resistance and adipokines in subjects with obesity.

Subjects and methods

Subjects

A population of 1027 obese (body mass index >= 30) non diabetic patients was analyzed in a prospective way. These patients were recruited in a Nutrition Clinic Unit and signed an informed consent. A Local ethical committee approved the protocol. Exclusion criteria included history of cardiovascular disease or stroke during the previous 36 months, total cholesterol >300 mg/dl, triglycerides >400 mg/dl, blood pressure >140/90 mmHg, fasting plasma glucose >110 mg/dl, as well as the use of drugs to treat diabetes mellitus, glucocorticoids, antineoplastic agents, angiotensin receptor blockers, angiotensin converting enzyme inhibitors and psychoactive medications.

Experimental design

All patients with a 2 weeks weight-stabilization period before recruitment were enrolled. Weight, blood pressure, basal glucose, c-reactive protein (CRP), insulin, insulin resistance (HOMA-IR), total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides and adipokines (leptin, adiponectin, resistin, TNF alpha, and interleukin 6) levels were measured in all subjects. A bioimpedance and a prospective serial assessment of nutritional intake with 3 days written food records were realized. Genotype of CNR2 receptor gene polymorphism was studied.

Analytical procedures

Plasma glucose levels were determined by using an automated glucose oxidase method (Glucose analyser 2, Beckman Instruments, Fullerton, CA). Insulin was measured by RIA (RIA Diagnostic Corporation, Los Angeles, CA) with a sensitivity of 0.5 mUI/L (normal range 0.5–30 mUI/L).
Dietary intake and habits

All enrolled subjects received instruction to record their daily dietary intake for three days including a weekend day. Handling of the dietary data was by means of a personal computer equipped with personal software, incorporating use of food scales and models to enhance portion size accuracy. Records were reviewed by a dietitian and analyzed with a computer-based data evaluation system. National composition food tables were used as a reference. The exercise was recorded by each subjects as total minutes per week of physical activity.

Statistical analysis

Sample size was calculated to detect differences over 4 kg in body weight with 90% power and 5% significance (n = 1000). The results were expressed as average ± standard deviation. The distribution of variables was analyzed with Kolmogorov–Smirnov test. Quantitative variables with normal distribution were analyzed with a two-tailed Student’s-t test. Quantitative variables were analyzed with an ANOVA test with three groups of genotype (GG, GA, AA) and Bonferroni test as a post hoc test. Non-parametric variables were analyzed with the Mann–Whitney U test. Qualitative variables were analyzed with the chi-square test, with Yates correction as necessary, and Fisher’s test. A p-value under 0.05 was considered statistically significant.

Results

One thousand and twenty seven obese subjects gave informed consent and were enrolled in the study. The mean age was 45.8 ± 13.1 years and the mean BMI 36.3 ± 5.2. All subjects were weight stable during the 2 weeks period preceding the study (body weight change, 0.18 ± 0.1 kg).

Three hundred and thirty nine patients (33.0%) had the genotype GG, 467 patients GA (45.5%) and 221 patients AA (21.5%). Age was similar in the 3 genotype groups (GG: 44.9 ± 11.6 years vs GA; 45.9 ± 12.8 years vs AA; 45.2 ± 9.6 years: ns). Sex distribution was similar in different genotype groups (GG; 22.9% males vs 77.1% females vs GA; 29.0% males vs 71.0% females vs AA; 28.6% males vs 71.4% females: ns). Table 1 shows the anthropometric variables. BMI, weight, fat mass and waist circumference were higher in A allele carriers than non-A allele carriers. No differences in anthropometric parameters were detected between GA and AA genotypes.

Table 2 shows the classic cardiovascular risk factors. Triglycerides, insulin and HOMA-IR values were higher in A allele carriers than non A allele carriers. No differences in biochemical parameters were detected between GA and AA genotypes.

Table 3 shows nutritional intake with 3 days written food records. No statistical differences were detected in caloric, carbohydrate, fat, and protein intakes. Aerobic exercise per week was similar in all groups.

Table 4 shows levels of adipocytokines. Leptin was higher in A allele carriers than non A allele carriers. No differences in leptin levels were detected between GA and AA genotypes.
**Table 1** Anthropometric variables.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>GG (n = 339)</th>
<th>GA (n = 467)</th>
<th>AA (n = 221)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td>35.8 ± 6.4</td>
<td>36.2 ± 6.1*</td>
<td>37.0 ± 6.0*</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>93.2 ± 15.2</td>
<td>94.9 ± 12.8*</td>
<td>96.8 ± 10.8*</td>
</tr>
<tr>
<td>Fat mass (kg)</td>
<td>38.6 ± 13.1</td>
<td>39.6 ± 11.9*</td>
<td>40.8 ± 10.9*</td>
</tr>
<tr>
<td>WC (cm)</td>
<td>110.9 ± 11.2</td>
<td>111.9 ± 12.5*</td>
<td>114.2 ± 14.1*</td>
</tr>
<tr>
<td>Waist to hip ratio</td>
<td>0.88 ± 0.1</td>
<td>0.89 ± 0.09</td>
<td>0.89 ± 0.09</td>
</tr>
</tbody>
</table>

WC: waist circumference. No statistical differences between groups.
* p < 0.05, AA or GA genotypes versus GG genotype.

**Table 2** Classical cardiovascular risk factors.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>GG (n = 339)</th>
<th>GA (n = 467)</th>
<th>AA (n = 221)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mg/dl)</td>
<td>99.8 ± 12.5</td>
<td>100.2 ± 9.3</td>
<td>99.5 ± 12.3</td>
</tr>
<tr>
<td>Total Ch. (mg/dl)</td>
<td>204.8 ± 32.1</td>
<td>203.5 ± 40.3</td>
<td>204.2 ± 36.3</td>
</tr>
<tr>
<td>LDL-Ch. (mg/dl)</td>
<td>127.1 ± 32.9</td>
<td>125.4 ± 35.2</td>
<td>126.3 ± 33.2</td>
</tr>
<tr>
<td>HDL-Ch. (mg/dl)</td>
<td>53.4 ± 21.1</td>
<td>54.3 ± 12.9</td>
<td>55.1 ± 11.9</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>121.3 ± 45.9</td>
<td>126.4 ± 34.1*</td>
<td>135.2 ± 40.8*</td>
</tr>
<tr>
<td>Insulin (mUI/L)</td>
<td>13.6 ± 9.1</td>
<td>14.1 ± 6.1</td>
<td>14.3 ± 5.9*</td>
</tr>
<tr>
<td>HOMA-IR (units)</td>
<td>3.45 ± 2.2</td>
<td>3.53 ± 1.5*</td>
<td>3.67 ± 1.2*</td>
</tr>
<tr>
<td>CRP (mg/dl)</td>
<td>6.3 ± 4.4</td>
<td>6.0 ± 3.4</td>
<td>5.3 ± 4.4</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>127.2 ± 12.1</td>
<td>127.8 ± 11.5</td>
<td>128.0 ± 10.5</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>81.4 ± 11.9</td>
<td>82.1 ± 9.4</td>
<td>82.3 ± 12.4</td>
</tr>
</tbody>
</table>

BP: blood pressure; Ch: cholesterol; TG: triglycerides; CRP: C reactive protein; HOMA-IR: homeostasis model assessment.
* p < 0.05, AA or GA genotypes versus GG genotype.

**Table 3** Dietary intake.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>GG (n = 339)</th>
<th>GA (n = 467)</th>
<th>AA (n = 221)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy (kcal/day)</td>
<td>1774.7 ± 637</td>
<td>1693 ± 533</td>
<td>1701 ± 533</td>
</tr>
<tr>
<td>CH (g/day)</td>
<td>178.1 ± 82.1</td>
<td>171.3 ± 60.6</td>
<td>170.3 ± 61.1</td>
</tr>
<tr>
<td>Fat (g/day)</td>
<td>75.5 ± 33.2</td>
<td>72.7 ± 32.1</td>
<td>71.3 ± 33.1</td>
</tr>
<tr>
<td>S-fat (g/day)</td>
<td>21.3 ± 12.1</td>
<td>21.9 ± 10.5</td>
<td>22.0 ± 11.5</td>
</tr>
<tr>
<td>M-fat (g/day)</td>
<td>35.5 ± 12.3</td>
<td>35.8 ± 12.5</td>
<td>36.8 ± 12.5</td>
</tr>
<tr>
<td>P-fat (g/day)</td>
<td>7.7 ± 4.2</td>
<td>7.3 ± 3.2</td>
<td>7.1 ± 3.2</td>
</tr>
<tr>
<td>Protein (g/day)</td>
<td>85.1 ± 21.2</td>
<td>84.4 ± 22.3</td>
<td>85.4 ± 21.1</td>
</tr>
<tr>
<td>Exercise (h/week)</td>
<td>1.7 ± 2.1</td>
<td>1.5 ± 2.0</td>
<td>1.6 ± 2.1</td>
</tr>
<tr>
<td>Dietary fiber</td>
<td>14.4 ± 6.0</td>
<td>14.3 ± 5.5</td>
<td>14.2 ± 6.5</td>
</tr>
</tbody>
</table>

CH: carbohydrate; S-fat: saturated fat; M-fat: monounsaturated fat; P-fat: polyunsaturated fat. No statistical differences between groups.

**Table 4** Circulating adipokines.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>GG (n = 339)</th>
<th>GA (n = 467)</th>
<th>AA (n = 221)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL 6 (pg/ml)</td>
<td>1.7 ± 1.4</td>
<td>1.7 ± 2.0</td>
<td>1.8 ± 1.9</td>
</tr>
<tr>
<td>TNF-alpha (pg/ml)</td>
<td>8.5 ± 4.2</td>
<td>9.5 ± 4.0</td>
<td>9.3 ± 4.2</td>
</tr>
<tr>
<td>Adiponectin (ng/ml)</td>
<td>19.2 ± 12.8</td>
<td>21.8 ± 10.4</td>
<td>20.1 ± 8.1</td>
</tr>
<tr>
<td>Resistin (ng/ml)</td>
<td>5.3 ± 1.2</td>
<td>5.4 ± 1.3</td>
<td>5.1 ± 1.1</td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>56.2 ± 36.8</td>
<td>66.8 ± 32.4*</td>
<td>69.1 ± 28.1*</td>
</tr>
</tbody>
</table>

IL-6, interleukin 6.
* p < 0.05, AA or GA genotypes versus GG genotype.
Discussion

The finding of this study is the association of the minor allele of SNP rs3123554 within the cannabinoid receptor subtype 2 (CNR2) gene with obesity parameters and higher levels of leptin, triglycerides, insulin and HOMA-IR.

The percentage of minor allele carriers over 50% was similar to other studies. The literature supports the notion that endocannabinoid system is positioned for regulation of endocannabinoid levels that could influence craving and reward behaviors through the relevant neuronal circuitry and metabolic parameters. Moreover, CNR2 has long been referred to as the peripheral cannabinoid receptor isoform. Interestingly, there is now evidence of CNR2 expression in different areas of the brain, but the physiological role remains largely unclear. In our study, we found the significant association of the SNP with obesity and metabolic parameters in the cross sectional cohort. Recently, a potential role of cerebral CNR2 receptors in the modulation of body weight was found in the animal model. Central CNR2 over expression leads to a lean phenotype in mice. Moreover, CNR2 activation in humans also seems to influence eating behavior. Our finding of an association of a SNP rs3123554 within the CNR2 gene and altered insulin resistance and body weight gives evidence of a metabolic role of the CNR2 in humans.

Insulin action is an important regulator of energy homeostasis and body weight. Ketterer et al. have found that carriers of minor allele of this SNP showed lower cerebral insulin sensitivity. One could speculate that altered cerebral insulin sensitivity in carriers of the minor allele of rs3123554 may be responsible for higher weight than non carriers.

A second hypothesis could be the possibility that the body weight effect in this cross-sectional study is due to peripheral metabolic mechanisms, because CNR2 has been isolated in organs important for the control of metabolism like adipose tissue, liver and skeletal muscle. The study of Ketterer et al. showed an inverse relation of minor allele of this SNP with body weight. However, this relationship was described only in females and in a population of obese subjects for high risk with diabetes mellitus type 2 or diagnosis of impaired fasting glycemia. Our sample has males and females without diabetes/impaired glycemia, these two parameters could explain the differences between both studies.

The inconsistencies between these studies may reflect the complex interactions between multiple population-specific genetic and environmental factors. Perhaps, these different results could be explained by inclusion criteria for subjects in other studies (diabetic vs non diabetic patients). This previous study would require composition analysis of the diet to determine whether dietary components could be responsible for the metabolic profiles. In our study dietary intake did not show statistical differences between groups, in this way we have controlled for dietary intake.

In our patients, insulin, HOMA-IR, leptin and triglycerides levels were higher in obese patients carrying the minor allele. As far as we known, this is the first time in the literature that this association has been reported and we considered that it could be explained with the association of A allele with higher body weight.

Recently, the CNR2 rs35761398 polymorphism, which leads to the CNR2 Q63R variant, revealed a significantly earlier age of menarche in subjects carrying the Q63 allele, which was also found after adjusting for BMI z-score. Logistic regression analysis demonstrated that patients homozygous for the Q allele had a 2.2-fold higher risk of presenting with an early menarche (age at menarche <12 years). Finally, rs3003336, rs2501431, rs2502992, rs2501432 SNPs of CNR2 genes are related in the etiology of osteoporosis and suggest that it may be a genetic risk factor for bone density and osteoporosis in postmenopausal women.

In conclusion, the novel finding of this study is the association of the minor allele of rs3123554 SNP within CNR2 gene with body weight and triglyceride, HOMA-IR, insulin and leptin levels. Further studies are needed to elucidate this complex relationship independently of body mass index and to explore potentially therapeutic implications such other SNPs in CNR1 pathway.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Funding

None.

Conflict of interest

The authors declare that they have no conflicts of interest.

References